Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data-Reference-Cited by-同舟云学术

Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data

Published:2020-06 Issue:11 Volume:146 Page:2968-2978
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Jongeneel Gabrielle¹^ORCID,Klausch Thomas¹,Erning Felice N.²,Vink Geraldine R.²³,Koopman Miriam³,Punt Cornelis J.A.⁴,Greuter Marjolein J.E.¹^ORCID,Coupé Veerle M.H.¹

Affiliation:

1. Department of Epidemiology and BiostatisticsAmsterdam UMC, VU University Amsterdam The Netherlands

2. Department of ResearchNetherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands

3. University Medical Center UtrechtUtrecht University Utrecht The Netherlands

4. Department of medical oncologyAmsterdam UMC, University of Amsterdam Amsterdam The Netherlands

Funder

ZonMw

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32629

Reference46 articles.

1. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. What is “quality of evidence” and why is it important to clinicians?

3. External validity of randomised controlled trials: “To whom do the results of this trial apply?”

4. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence

5. Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months;European Journal of Cancer;2024-09

2. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer;Therapeutic Advances in Medical Oncology;2024-01

3. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study;Clinical Cancer Research;2022-05-18

4. Training with Small Medical Data: Robust Bayesian Neural Networks for Colon Cancer Overall Survival Prediction;2021 43rd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC);2021-11-01

5. Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey;Cancers;2021-10-30